Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:CAR_T-cell_therapy
|
| gptkbp:approves |
gptkb:2017
multiple countries B-cell acute lymphoblastic leukemia diffuse large B-cell lymphoma |
| gptkbp:associated_with |
emotional support
patient education treatment response clinical outcomes therapeutic efficacy research advancements treatment guidelines survivorship issues quality of life considerations long-term follow-up remission rates potential for cure |
| gptkbp:clinical_trial |
gptkb:ECOG-ACRIN_E1910
Phase 2 ELIANA trial TRANSCEND trial |
| gptkbp:clinical_use |
oncology
|
| gptkbp:developed_by |
gptkb:Novartis
patient's own T-cells |
| gptkbp:duration |
variable
|
| https://www.w3.org/2000/01/rdf-schema#label |
tisagenlecleucel
|
| gptkbp:indication |
relapsed or refractory B-cell malignancies
|
| gptkbp:influenced_by |
gptkb:guidelines
|
| gptkbp:involves |
gptkb:virus
data collection patient safety risk assessment clinical assessment genetic modification follow-up care patient monitoring multidisciplinary team patient selection T-cell expansion adverse event management cell collection |
| gptkbp:is_monitored_by |
post-infusion complications
|
| gptkbp:is_subject_to |
health insurance coverage
|
| gptkbp:manufacturer |
GMP facilities
|
| gptkbp:marketed_as |
gptkb:Kymriah
|
| gptkbp:mechanism_of_action |
modifies T-cells to attack cancer cells
|
| gptkbp:origin |
gptkb:USA
|
| gptkbp:patient_population |
pediatric and young adult patients
|
| gptkbp:price |
high
|
| gptkbp:regulatory_compliance |
gptkb:FDA
gptkb:EMA |
| gptkbp:requires |
informed consent
hospitalization pre-treatment lymphodepletion |
| gptkbp:research_focus |
gptkb:immunotherapy
|
| gptkbp:route_of_administration |
intravenous
|
| gptkbp:side_effect |
cytokine release syndrome
neurological events |
| gptkbp:targets |
gptkb:CD19
|
| gptkbp:type |
gptkb:gene_therapy
|
| gptkbp:used_in |
clinical practice
|
| gptkbp:bfsParent |
gptkb:Yescarta
|
| gptkbp:bfsLayer |
5
|